Zavain Dar

investing in tech and life science companies

📍 New York, New York, United States🔄 Updated September 2026💼 13 investments📅 12 years investing🗓 Last invested Apr 2021
VC🌍 United States
13
Total investments
6
Early stage
5
Mid stage
0
Late stage
12y
Years active

Portfolio

12 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Apr 2021
Building high-performance genetic technologies that transform patient lives.
Board Observer
Oct 2019
The AI community building the future.
Investor
Jul 2018
HIPAA, GDPR and Data Residency requirements restrict your ability to conduct data science. CryptoNumerics removes these restrictions. CryptoNumerics enables you to create privacy protected datasets with quantifiable privacy risk. In addition, you can build statistical and machine learning models that protect people’s privacy. Our team consists of engineers and visionaries with previous experience in C-Level roles at Fortune 500 companies, founding teams of venture backed growth stage start-ups, and accomplished R&D leaders.
Investor
May 2018
Your health plan doesnt have to suck. Health plans built around Direct Primary Care.
Investor
Mar 2018
Computable Labs develops blockchain and distributed systems technology to build a decentralized data marketplace for artificial intelligence applications. Data has become the most precious resource of our time, and we believe creating a new Internet substrate for structuring and sharing data will unlock not only unprecedented enterprise value, but also scientific progress and social equity.
Board Observer
2018
We are building AI to simulate the world through merging art and science. We believe that world models are at the frontier of progress in artificial intelligence. Language models alone won’t solve the world’s hardest problems – robotics, disease, scientific discovery. Real progress requires models that experience the world and learn from their mistakes, the same way that humans do. And this kind of trial and error can be massively accelerated when done in simulation, rather than in the real world. World models offer the most clear path to general-purpose simulation, changing how stories are told, how scientific progress is made and how the next frontiers of humanity are reached. https://runwayml.com/world-simulator
Board Observer
Oct 2016
Clarifai is an independent artificial intelligence company that specializes in computer vision, natural language processing, and audio recognition. One of the first deep learning platforms having been founded in 2013, Clarifai provides an AI platform for unstructured image, video, text, and audio data. Its platform supports the full AI lifecycle for data exploration, data labeling, model training, evaluation, and inference around images, video, text, and audio data. Headquartered in Washington DC, Clarifai uses machine learning and deep neural networks to identify and analyze images, videos, text, and audio automatically. Clarifai enables users to implement AI technology into their products via API, Mobile SDK, and/or on-premise solutions.
Investor
Mar 2016
Rigetti is a pioneer in full-stack quantum computing. Rigetti quantum computers are based on superconducting qubits, which are widely believed to be the leading qubit modality given their maturity, clear path to scaling, and fast gate speeds. Current Rigetti quantum computing systems achieve gate speeds of 50-70ns, which is about 1,000 times faster than other modalities such as ion traps and neutral atoms. Rigetti sells on-premises 9-qubit to 108-qubit quantum computing systems, supporting national laboratories and quantum computing centers. Rigetti’s Cepheus 36-qubit to 108-qubit systems are based on the Company’s proprietary chiplet-based technology and include the Company’s control electronics. Rigetti’s 9-qubit Novera QPU supports a broader R&D community with a high-performance, on-premises QPU designed to plug into a customer’s existing cryogenic and control systems. The Company operates quantum computers over the cloud through its Rigetti Quantum Cloud Services (QCS) platform, enabling global enterprise, government, and research clients to pursue R&D. The Company’s proprietary quantum-classical infrastructure provides high-performance integration with public and private clouds for practical quantum computing. Rigetti developed the industry’s first multi-chip quantum processor for scalable quantum computing systems. Leveraging this proprietary technology, Rigetti deployed the industry’s largest multi-chip quantum computer in 2025 with Cepheus-1-36Q, based on four 9-qubit chiplets tiled together. The Company designs and manufactures its chips in-house at Fab-1, the industry’s first dedicated and integrated quantum device manufacturing facility.
Angel Investor
Jun 2015
Tala is the first financial platform for the Global Majority. Our leading money app bridges digital and cash ecosystems to deliver instant access to credit, payments, savings, and transfer services to millions of customers on three continents. Powered by advanced technology and human creativity, Tala is reinventing financial infrastructure to solve what legacy institutions can’t or won’t, in order to unlock global economic progress. Tala has raised nearly half a billion dollars in investments and debt, backed by leading venture and impact investors including Upstart, the Stellar Development Foundation, RPS Ventures, the J. Safra Group, IVP, Revolution Growth, Lowercase Capital, and PayPal Ventures. Tala has been named to Fortune’s Impact 20, CNBC’s Disruptor 50 list four years in a row, and Forbes’ Fintech 50 list for eight consecutive years. Tala’s impact has been highlighted by the New York Times, NPR, Forbes, the Financial Times, the Wall Street Journal and TED, among others. Tala is headquartered in Santa Monica with offices in Nairobi, Manila, Mexico City, and Bangalore.
Board Observer
Jan 2015
We are a clinical-stage, AI-native biopharma that mines massive data for therapeutic gold to raise the standard of cancer care. Our platform uses AI and available, heterogenous human disease data to uncover novel drug candidates for the most responsive patients, leading to smarter drug discovery that maximizes clinical trial success. We are currently focused on advancing better therapies for cancers and cancer-related diseases. Our lead program, AU-409, for liver cancer, is in Phase 1 clinical studies.
Angel Investor
Oct 2014
Zymergen is now a part of Ginkgo Bioworks!
Board Observer
Jan 2014
Zymergen is now a part of Ginkgo Bioworks!
Experience · 17 entries
All (17)
Investments (13)
Founder (2)
Board (5)
2022
Venture Partner
Mar 2022
Lux Capital is a venture capital firm investing in emerging science and technology at the outermost edges of what is possible. They partner with iconoclastic inventors who challenge the status quo and the laws of nature to bring their futuristic ideas to life. Over the past two decades, Lux has expanded from its New York City roots to Silicon Valley, and built a $7 billion AUM firm of more than 30 full-time professionals, with a wide spectrum of technical backgrounds and the versatility to invest at any stage. Press inquiries: comms@luxcapital.com.
Founder
Mar 2022
A first-of-its-kind fund partnering with founders at the interface of technology and life sciences to transform the trajectory of life on earth
2021
Investor
Apr 2021
Building high-performance genetic technologies that transform patient lives.
2020
Thrive Earlier Detection Corp.
Investor
Jul 2020
2019
Board Observer
Oct 2019
The AI community building the future.
Show all 17 entries ↓
Investment activity
2014–2021 · 13 investments
20142201522016220184201912020120211
Recent (last 2 years)Earlier